Story Poster
Notre Dame Football Recruiting

Notre Dame QB Signee Kenny Minchey Ready For All-American Test

December 29, 2022
10,515

Kenny Minchey‍ is ready to get up to South Bend as an early enrollee after signing with Notre Dame last week, but the 2023 quarterback from Tennessee has one more game as a high-schooler before he does so.

The Pope John Paul II star will be in San Antonio next week preparing to play in the All-American Bowl at the Alamodome on Saturday, Jan. 7th.

“It was a great honor,” Minchey said of being selected to play in the showcase event. “Growing up, you see people who are All-Americans and you think, ‘Wow, that’s crazy!’

“Now, they’ve selected me to be an All-American, so it feels kind of surreal. I feel like it’s just a representation of all the hard work I’ve put in.”

The 6-foot-2, 207-pounder is looking forward to being able to play with and against some of the nation’s top players.

“I think it’ll be good,” he said. “Obviously, the competition is going to be the best of the best down there.

“It’ll be good to be able to throw to good receivers, but also be able to play against good linebackers and DBs and be able to test myself.”

While the on-field competition will help him prepare for the next level, he’s also looking forward to spending time with his future teammates and opponents.

“The college atmosphere of being around other top guys,” he said of what he’s excited about.

“A few of the Notre Dame guys are going to be down there as well, so I’ll be able to see them before we actually go play in college together.”

Minchey is one of eight Notre Dame signees who were selected to the event. He will be joined by defensive linemen Boubacar Traore‍ and Brenan Vernon‍, defensive backs Adon Shuler‍ and Micah Bell‍, wide receiver Rico Flores Jr.‍, linebacker Drayk Bowen‍ and offensive lineman Charles Jagusah‍.

Under Armour Green Fighting Irish Lightweight Performance Quarter-Zip ($79.99)

 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.